Board of Directors

Dr. Caforio, age 52, serves as chairman of Bristol-Myers Squibb’s Board of Directors.

Dr. Caforio has been our Chief Executive Officer since May 2015. He was our Chief Executive Officer Designate from January to May 2015, our Chief Operating Officer from June 2014 to May 2015, and he served as Executive Vice President and Chief Commercial Officer from November 2013 to June 2014.

From October 2011 to November 2013, he served as President, U.S. He held the position of Senior Vice President, Global Commercialization and Immunology from May 2010 to October 2011. Prior to that, he served as Senior Vice President, Oncology, U.S. and Global Commercialization from March 2009 to May 2010.

From January 2007 to March 2009 he served as Senior Vice President, U.S. Oncology and from May 2004 to January 2007, he served as Senior Vice President, European Marketing and Brand Commercialization.

Dr. Caforio is a member of the Board of Trustees of the Pharmaceutical Research and Manufacturers of America (PhRMA).

Mr. Arduini, age 52, has been President and Chief Executive Officer of Integra LifeSciences Holdings Corporation, a global medical technology company, since January 2012 and currently serves as a member of Integra’s Board of Directors.

He served as President and Chief Operating Officer of Integra from November 2010 to January 2012. Before joining Integra, Mr. Arduini was Corporate Vice President and President of Medication Delivery, Baxter Healthcare, from 2005 to 2010.

Prior to joining Baxter, Mr. Arduini worked for General Electric Healthcare, where he spent much of his 15 years in a variety of management roles for domestic and global businesses, culminating in leading the global functional imaging business.

Mr. Arduini also serves on the Board of Directors of ADVAMED (the Advanced Medical Technology Association), the Board of Directors of MDIC (the Medical Device Innovation Consortium), and the Board of Directors of the National Italian American Foundation.

Robert Bertolini, age 55, brings to the Board significant experience in strategic and operational leadership both in and out of the finance function. Most recently, he was President and Chief Financial Officer of Bausch & Lomb, the global eye health company, where he played a key role in preparing the company for an initial public offering until its sale to Valeant Pharmaceuticals. Previously, Mr. Bertolini served as Executive Vice President and Chief Financial Officer at Schering-Plough Corporation, where he oversaw all key financial areas and played a key role in transforming operations and leading the acquisition of a significant business. Prior to joining Schering-Plough, Mr. Bertolini spent 20 years at PricewaterhouseCoopers LLP, leading a global organization of professionals and partners serving the pharmaceutical industry and other health-related industries. Mr. Bertolini has a Bachelor’s Degree in Economics from Rutgers, is a Certified Public Accountant licensed in New York and New Jersey, is a current Board member of Charles River Labs and Idorsia Ltd, and a former Board Member of Actelion Pharmaceuticals, Genzyme Corporation and the New Jersey Performing Arts Center.

Matthew Emmens, age 65, brings to the Board more than 40 years of experience in the biopharmaceutical industry, with significant management, business development and operations expertise. Mr. Emmens began his career in international pharmaceuticals with Merck & Co., Inc., where he helped to establish Astra Merck, the joint venture between Merck and Astra AB of Sweden, later becoming its President and CEO. A recognized biotech and pharma leader, Mr. Emmens served as President, Pharmaceuticals, for Merck KGaA; CEO and Chairman of Shire PLC; and President, CEO and Chairman of Vertex Pharmaceuticals. While at Shire, Mr. Emmens engineered an extraordinary revitalization, transforming Shire into one of the top specialty biopharma companies in the world. Mr. Emmens holds a B.S. in Business Management from Fairleigh Dickinson University.

Dr. Glimcher, age 65, is currently the President and Chief Executive Officer of Dana-Farber Cancer Institute and the Richard and Susan Smith Professor of Medicine, Harvard Medical School as of October 1, 2016.

She had previously served as the Advisor to the Interim Dean and Provost for Medical Affairs and Advisor to the Chairman of the Board of Overseers of Weill Cornell Medical College since June 1, 2016.

She served as the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College and the Cornell University Provost for Medical Affairs from 2012 to 2016. Dr. Glimcher was the Irene Heinz Given Professor of Immunology at the Harvard School of Public Health and Professor of Medicine at Harvard Medical School from 1990 to December 2011.

She is a Fellow of the American Academy of Arts and Sciences, a member of the National Academy of Sciences USA, and a member of the Institutes of Medicine of the National Academy of Sciences. She is also a member and past President of the American Association of Immunologists.

She was elected to the American Society of Clinical Investigation, the American Association of Physicians and the American Association for the Advancement of Science. Dr. Glimcher is a Director of Waters Corporation.

Mr. Grobstein, age 74, is a retired Vice Chairman of Ernst & Young LLP, an independent registered public accounting firm. Mr. Grobstein worked with Ernst & Young from 1964 to 1998, and was admitted as a partner in 1975.

He served as a Vice Chairman International Operations from 1993 to 1998, as Vice Chairman Planning, Marketing and Industry Services from 1987 to 1993, and Vice Chairman Accounting and Auditing Services from 1984 to 1987.

He serves on the Board of Trustees and Executive Committee and is the Treasurer of the Central Park Conservancy.

He also serves on the Board of Directors of the Peer Health Exchange, Inc. Mr. Grobstein is a Director of Mead Johnson Nutrition Company.

Mr. Lacy, age 63, is currently the Non Executive Chairman of Dave & Buster’s Entertainment Inc. and previously served as the Chairman and Chief Executive Officer of Sears, Roebuck and Co. and the Vice Chairman and Chief Executive Officer of its successor, Sears Holdings Corporation, from 2000 to 2005.

Mr. Lacy also served as Vice Chairman of Sears Holdings Corporation from 2005 to 2006. More recently, Mr. Lacy served as Senior Advisor to Oak Hill Capital Partners, L.P., a private equity investment firm, from 2007 to 2014.

He is Trustee of Fidelity Funds and the California Chapter of The Nature Conservancy.

Mr. Lacy is a Director of the Center for Advanced Study in the Behavioral Sciences at Stanford University.

Mr. Paliwal, age 59, has served as Chairman, President and Chief Executive Officer of Harman International Industries, Inc., the connected technologies company for automotive, consumer and enterprise markets, since July 2008. Mr. Paliwal has served as President and Chief Executive Officer of Harman since July 2007.

Prior to joining Harman, Mr. Paliwal served as a member of the Group Executive Committee of ABB Ltd., a provider of industrial automation, power transmission systems and services, from January 2001 until June 2007.

Mr. Paliwal also served as President of Global Markets and Technology of ABB Ltd. from January 2006 until June 2007, as Chairman and Chief Executive Officer of ABB North America from January 2004 until June 2007, and as President and Chief Executive Officer of ABB Automation Technologies Division from October 2002 to December 2005.

Mr. Paliwal serves on the board of the Business Advisory Council of the Farmer School of Business, Miami University and the U.S. India Business Council (USIBC) board of directors. He also is a member of the CEO Business Roundtable in Washington, D.C., and the U.S. India CEO Forum.

With more than 35 years in the financial industry, Theodore (Ted) Samuels, age 62, brings to the Board extensive business and operational experience, particularly with respect to economics, capital markets and investment decision making. Mr. Samuels is the former President of Capital Guardian Trust Company and a former global equity portfolio manager at Capital Group, one of the most prominent investment management organizations in the world. Mr. Samuels currently serves as a Director at Perrigo Company, PLC, and Stamps.com; and while at Capital Group served on many management and investment committees, with an eye towards long-term shareholder value creation. Mr. Samuels received his Bachelor’s degree from Harvard College and a Master of Business Administration degree from Harvard Business School.

Dr. Sato, age 68, has served as a professor of management practice at the Harvard Business School since July 2005. From July 2005 to October 2014 she served as professor of the practice of molecular and cell biology at Harvard University.

In 2005, Dr. Sato retired as President of Vertex Pharmaceuticals Incorporated, a global biotechnology company, where she was responsible for research and development, business and corporate development, commercial operations, legal, and finance.

Dr. Sato also served as Chief Scientific Officer, Senior Vice President of Research and Development, and Chair of the Scientific Advisory Board at Vertex before being named President in 2000.

Dr. Sato is a Director of PerkinElmer Corporation and BorgWarner, Inc.

Mr. Storch, age 60, has served as Chief Executive Officer of Hudson’s Bay Company since January 2015, a leading owner and operator of department stores including Saks Fifth Avenue, Lord & Taylor, Hudson’s Bay Department Stores, Home Outfitters, Saks OFF 5th, Kaufhof, Inno, and the e commerce business Gilt.

From November 2013 to January 2014 he served as Chairman and Chief Executive Officer of Storch Advisors. He also served as Chairman of Toys“R”Us, Inc. from February 2006 to November 2013 and Chief Executive Officer of Toys“R”Us from February 2006 to May 2013.

Prior to joining Toys“R”Us, Mr. Storch served as Vice Chairman of Target Corporation. He joined Target in 1993 as Senior Vice President of Strategy and served in roles of increasing seniority over the next 12 years. Prior to joining Target, Mr. Storch was a partner at McKinsey & Company.

He is a Director of Fanatics, Inc. Mr. Storch is a Director of Supervalu, Inc.